查看文章

The British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and the Systemic Lupus Erythematosus (SLE) Responder Index (SRI-4) are measures of response used as primary endpoints in randomized controlled trials (RCTs) within SLE. BICLA enables incremental response assessment, while SRI-4 reflects response based on the presence or absence of a lupus manifestation rather than its severity [1, 2].

The purpose of this study was to determine belimumab efficacy assessed using BICLA in patients with SLE included in the phase III belimumab RCTs, in which SRI-4 outcomes were originally assessed.

A post-hoc meta-analysis was carried out using data from five RCTs of belimumab in active adult SLE: four with intravenous (IV) belimumab (BLISS-52 [3], BLISS-76 [4], BLISS-Northeast Asia (NEA) [5], and EMBRACE [6]), and one with …